Hydrazide-containing CFTR inhibitor compounds and uses thereof

Details Hydrazide-containing CFTR inhibitor compounds and uses thereof Hydrazide-containing CFTR inhibitor compounds and uses thereof

2005-03-29

2008-08-19

Eyler, Yvonne (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S313000, C514S563000, C514S614000

Reexamination Certificate

active

07414037

ABSTRACT:
The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

REFERENCES:
patent: 5023333 (1991-06-01), Hubele
patent: 6172108 (2001-01-01), Vega et al.
patent: 6331555 (2001-12-01), Hirth et al.
patent: 0 952 159 (1999-10-01), None
patent: 1 334 400 (1973-10-01), None
patent: 1446980 (1976-08-01), None
patent: 2 107 074 (1983-04-01), None
patent: 59-162541 (1984-09-01), None
patent: WO 01/30333 (2001-05-01), None
patent: WO 0130333 (2001-05-01), None
Beresnevicius et al., {Interaction of aminoquinolines with unsaturated carboxylic acids. 1. Synthesis of N-quinolyl-b-alanines and their biological activity, Chemistry of Heterocyclic Compounds (New York)(Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2000), 36(4), 432-438}.
Aminabhavi et al., {Synthesis and characterization of biologically active organosilicon and organotin complexes of phenylglycyl hydrazones, Inorganica Chimica Acta (1987), 135(2), 139-43}.
Hammam et al., {Synthesis and reactions of 1,2,4-oxadiazole derivatives of expected biological activity, Egyptian Journal of Chemistry (1985), 27(3), 407-11}.
Verma et al., {Syntheses and anti-inflammatory activities of substituted arylamino-(N′-benzylidene)acetohydrazides and derivatives, Archiv der Pharmazie (Weinheim, Germany) (1984),317(10), 890-4}.
Solomko et al., {N-Aryl-b-amino acids. V. Hydrazides of N-aryl-b-alanines, Khimiko-Farmatsevticheskii Zhurnal (1971), 5(11), 18-21}.
Misra et al., {1,3,5-S-Triazine. Synthesis of some possible antituberculous compounds, Journal of the Indian Chemical Society (1971), 48(5), 448-50}.
Giri et al., {Organo-fluorine compounds. I. Synthesis of some substituted glycines and related compounds of potential biological activity, Journal of the Indian Chemical Society (1969), 46(5), 441-443}.
Misra et al., Possible antituberculous compounds. XV. N-2-Thiazolylglycines, 1-acyl-4-arylsemicarbazides, 1-acyl-4-arylthiosemicarbazides, and N1-(N-arylglycyl)-N2-(arylidane or alkylidene)hydrazines, J. Indian Chem. Soc. (1963), 40(9), 799-802.
Brock, M. W. et al., “Selective Open-channel Block ofShaker(Kv1) Potassium Channels by S-nitrosodithiothreitol (SNDTT),”J. Gen. Physiol., 118:113-133, Jul. 2001.
Chao, A. C. et al., “Activation of intestinal CFTR CI-channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase,”The EMBO Journal., 13(5):1065-1072, Mar. 1, 1994.
Dawson, D. C. et al., “CFTR: Mechanism of Anion Conduction,”Physiological Reviews, 79(Supp No. 1):S47-S75, Jan. 1999.
Grubb, B. R. And Boucher, R. C., “Pathophysiology of Gene-Targeted Mouse Models for Cystic Fibrosis,”Physiological Reviews, 79(Supp No. 1):S193-S214, Jan. 1999.
Jayaraman, S. et al., “Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na+] and pH but elevated viscosity,”PNAS, 98(14):8119-8123, Jul. 3, 2001.
Kimberg, D. V. et al., “Stimulation of Intestinal Mucosal Adenyl Cyclase by Cholera Enterotoxin and Prostglandins,”The Journal of Clinical Investigation, 50:1218-1230, 1971.
Lohi, H. et al., “Upregulation of CFTR expression but not SLC26A3 and SLC9A3 in ulcerative colitis,”Am. J. Physiol Gastrointest Liver Physiol., 283:G567-G575, 2002.
Ma, T. et al., “High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening,”The Journal of Biological Chemistry, 277(40):37235-37241, Oct. 4, 2002.
Ma, T. et al., “Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion,”The Journal of Clinical Investigation, 110(11):1651-1658, Dec. 2002.
McCarty, N. A., “Permeation Through the CFTR Chloride Channel,”The Journal of Experimental Biology, 203:1947-1962, 2000.
Muanprasat, C. et al., “Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure-Activity Analysis, and In Vivo Efficay,”J. Gen. Physiol., 124:125-137, Aug. 2004.
Noone, P. G. And Knowles, M. R., “‘CFTR-opathies’: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations,”Respir. Res., 2:328-332, 2001.
Pilewski, J. M. and Frizzell, R. A., “Role of CFTR in Airway Disease,”Physiological Reviews, 79(Supp No. 1):S215-S255, Jan. 1999.
Pottosin, I. I. et al., “Cooperative Block of the Plant Endomembrane Ion Channel by Ruthenium Red,”Biophysical Journal, 77:1973-1979, Oct. 1999.
Rabe, A. et al., “Cl-channel Inhibition by glibenclamide is not specific for the CFTR-type Cl-channel,”Pflügers Arch—Eur. J. Physiol, 429:659-662, 1995.
Ramamurthy, B. and Bhatt, M. V., “Synthesis and Antitubercular Activity ofN-(2-Naphthyl)glycine Hydrazide Analogues,”Journal of Medicinal Chemistry, 32:2421-2426, 1989.
Sheppard, D. N. and Robinson, K. A., “Mechanism of glibenclamide inhibition of cystic fibrosis transmembrane conductance regulator Cl-channels expressed in a murine cell line,”Journal of Physiology, 503.2:333-346, 1997.
Shultz, B. D. et al., “Pharmacology of CFTR Chloride Channel Activity,”Physiological Reviews, 79(Supp No. 1):S109-S144, Jan. 1999.
Snyder, J. D. and Merson, M. H., “The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data,”Bulletin of the World Health Organization, 60(4):605-613, 1982.
Spira, W. M. et al., “Simple Adult Rabbit Model forVibrio choleraeand EnterotoxigenicEscherichia coliDiarrhea,”Infection and Immunity, 32(2):739-747, May 1981.
Verma, M. et al., “Synthesis and Anti-inflammatory Activities of Substituted Arylamino-[N′-benzylidene)acetohydrazides and Derivatives,”Arch. Pharm.(Weinheim), 317:890-894, 1984.
Wong, P. Y. D., “CFTR gene and male fertility,”Molecular Human Reproduction, 4(2):107-110, 1998.
Yang, H. et al., “Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating,”The Journal of Biological Chemistry, 278(37):35079-35085, Sep. 12, 2003.
Zhou, Z. et al., “Probing an Open CFTR Pore with Organic Anion Blockers,”J. Gen. Physiol., 120:647-662, Nov. 2002.
CAS Registry No. 664312-09-8, Mar. 18, 2004.
CAS Registry No. 643741-81-5, Jan. 30, 2004.
CAS Registry No. 610257-12-0, Oct. 29, 2003.
CAS Registry No. 601498-97-9, Oct. 9, 2003.
CAS Registry No. 595552-29-7, Sep. 30, 2003.
CAS Registry No. 594871-24-6, Sep. 29, 2003.
CAS Registry No. 594870-13-0, Sep. 29, 2003.
CAS Registry No. 640704-49-0, Jan. 23, 2004.
CAS Registry No. 640698-93-7, Jan. 23, 2004.
CAS Registry No. 606483-72-1, Oct. 19, 2003.
CAS Registry No. 601498-88-8, Oct. 9, 2003.
CAS Registry No. 595553-21-2, Sep. 30, 2003.
CAS Registry No. 595550-90-6, Sep. 30, 2003.
CAS Registry No. 594870-90-3, Sep. 29, 2003.
CAS Registry No. 594869-56-4, Sep. 29, 2003.
Aminabhavi, T.M. et al., “Synthesis and Characterization of Biol

Affiliated with

Also associated with

Rating

Hydrazide-containing CFTR inhibitor compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydrazide-containing CFTR inhibitor compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrazide-containing CFTR inhibitor compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4013180